It was a tough day for analyst sentiment as several Wall Street banks reconsidered their positions on companies ranging from payment processors to homebuilders. When the downgrades came through Thursday, they painted a picture of analysts getting more cautious across multiple sectors.

PayPal Loses Its Champion

The headline move came from JP Morgan analyst Tien-Tsin Huang, who downgraded PayPal Holdings, Inc. (PYPL) from Overweight to Neutral and slashed the price target from $85 to $70. This is particularly notable since PayPal shares closed Wednesday at $61.24, meaning even the reduced target implies some upside. But the shift from "Overweight" to "Neutral" signals Huang no longer sees PayPal as a compelling buy relative to other opportunities.

Homebuilder Hits a Rough Patch

JP Morgan was busy Thursday. Analyst Michael Rehaut also downgraded Lennar Corporation (LEN) from Neutral to Underweight, lowering the price target from $118 to $115. That's especially striking given that Lennar shares closed at $133.13 on Wednesday, trading well above even the previous target. An "Underweight" rating is Wall Street speak for expecting the stock to underperform, suggesting Rehaut sees potential downside ahead for the homebuilder.

Real Estate Cools Down

Mizuho analyst Vikram Malhotra downgraded EastGroup Properties, Inc. (EGP) from Outperform to Neutral and cut the price target from $180 to $172. EastGroup Properties shares closed at $179.24 on Wednesday, right in that range. The move to Neutral suggests Malhotra sees the industrial REIT as fairly valued rather than poised for outperformance.

Industrial Sector Reassessment

Barclays analyst Julian Mitchell downgraded Pentair plc (PNR) from Overweight to Equal-Weight and slashed the price target from $127 to $115. Pentair shares closed at $106.47 on Wednesday, already trading below both targets. The industrial equipment maker is apparently facing a tougher road ahead in Mitchell's view.

Biotech Loses Momentum

Guggenheim analyst Brad Canino downgraded Black Diamond Therapeutics, Inc. (BDTX) from Buy to Neutral. Black Diamond Therapeutics shares closed at $2.69 on Wednesday. While Canino didn't announce a new price target, the shift away from a Buy rating suggests less conviction in the biotech's near-term prospects.

These downgrades reflect analysts recalibrating their expectations across diverse sectors. Whether it's fintech payment processing, residential construction, commercial real estate, industrial manufacturing, or biotech drug development, Wall Street's outlook got a bit cloudier for these five names Thursday.